
NRC FORM 374

## U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 4 PAGES Amendment No. 24

## MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.



11. The Radiation Safety Officer (RSO) for this license is Kerry Krugh, Ph.D., DABR.

MATERIALS LICENSE SUPPLEMENTARY SHEET       Learnse Number 21-16642-01       Docket or Reference Number 030-11390         12. Licensed material shall only be used by, or under the supervision of A Individuals permitted to work as authorized users on the material and medical uses as indicated:       A         A Individuals permitted to work as authorized users for the material and medical uses as indicated:       Material and Use         Matthew G. Aagensen, M.D.       10 CFR 35 100,10 CFR 35 200         Debra Achinger, M.D.       10 CFR 35 100,10 CFR 35 200         Zakaria Ismail Assi, M.D.       10 CFR 35 100,10 CFR 35 200         Garett Begeman, M.D.       10 CFR 35 100,10 CFR 35 200         James F. Bingle, M.D.       10 CFR 35 100,10 CFR 35 200         James F. Bingle, M.D.       10 CFR 35 100,10 CFR 35 200         James F. Bingle, M.D.       10 CFR 35 100,10 CFR 35 200         James F. Bingle, M.D.       10 CFR 35 100,10 CFR 35 200         James F. Bingle, M.D.       10 CFR 35 100,10 CFR 35 200         Jame Desenser, M.D.       10 CFR 35 100,10 CFR 35 200         Darked Disson, M.D.       10 CFR 35 100,10 CFR 35 200         Jame J. Belsendetti, M.D.       10 CFR 35 100,10 CFR 35 200         Darkel Desenser, M.D.       10 CFR 35 100,10 CFR 35 200         Darkel Desenser, M.D.       10 CFR 35 100,10 CFR 35 200         Darekel Dissine, M.D.       10 CFR 35 100,10 CFR 35 200 <th colspan="3">NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION</th> <th>PAGE 2 OF 4 PAGES</th>	NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION			PAGE 2 OF 4 PAGES
SUPPLEMENTARY SHEET       Amendment No. 24         12. Licensed material shall only be used by, or under the supervision of:       A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.         B. The following individuals are authorized users for the material and medical uses as indicated:       Material and Use         Matthew G. Aagensen, M.D.       Material and Use         Debra Achinger, M.D.       10 CFR 35.100 10 CFR 35.200         Zakaria Ismail Assi, M.D.       10 CFR 35.100,10 CFR 35.200         Material and Use       10 CFR 35.100,10 CFR 35.200         James F. Bingle, M.D.       10 CFR 35.100,10 CFR 35.200         David R. Cervantes, M.D.       10 CFR 35.100,10 CFR 35.200         David R. Cervantes, M.D.       10 CFR 35.100,10 CFR 35.200         Daniel Desener, M.D.       10 CFR 35.100,10 CFR 35.200         Desmiel Desener, M.D.       10 CFR 35.100,10 CFR 35.2				
A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.         B. The following individuals are authorized users for the material and medical uses as indicated:         Authorized User(M.D., D.O., etc.)         Matthew G. Aagensen, M.D.         Debra Achinger, M.D.         Jakaria Ismail Assi, M.D.         Garett Begeman, M.D.         James F. Bingle, M.D.         James T. Bingle, M.D.		Amendment No. 24		
Farhad Ebrahim, M.D.       10 CFR 35.100,10 CFR 35.200         Stephen Eldridge, M.D.       10 CFR 35.100,10 CFR 35.200         Murray Howe, M.D., Ph.D.       10 CFR 35.100,10 CFR 35.200	<ul> <li>SUPPLEMENTARY SHEET</li> <li>12. Licensed material shall only be used by,</li> <li>A. Individuals permitted to work as auth</li> <li>B. The following individuals are authoriz</li> <li><u>Authorized User(M.D.,D.O.,etc.)</u> Matthew G. Aagensen, M.D.</li> <li>Debra Achinger, M.D.</li> <li>Debra Achinger, M.D.</li> <li>Zakaria Ismail Assi, M.D.</li> <li>Garett Begeman, M.D.</li> <li>Paul Berlacher, M.D.</li> <li>James F. Bingle, M.D.</li> <li>David R. Cervantes, M.D.</li> <li>Donald L. Cox, M.D.</li> <li>Amy Culler, M.D.</li> <li>Laura DeBenedetti, M.D.</li> <li>Debra M. Dillon, D.O.</li> <li>Robert DiSalle, M.D.</li> </ul>	Amendment No. 24 or under the supervision of: norized users in accordance with 10 CPR zed users for the material and medical us <u>Material and Use</u> 10 CFR 35.100,10 CFR 35.200 10 CFR 35.100,10 CFR 35.200 10 CFR 35.100,10 CFR 35.200 10 CFR 35.200 10 CFR 35.100,10 CFR 35.200	35.13 and 10 CFR 35.14. ses as indicated:	
	Farhad Ebrahim, M.D. Stephen Eldridge, M.D. Murray Howe, M.D., Ph.D.	10 CFR 35.100,10 CFR 35.200 10 CFR 35.100,10 CFR 35.200		

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMM	ISSION	PAGE 3 OF 4 PAGES
MATERIALS LICENSE	License Number 21-16642-01	Docket or Reference Number 030-11390	
SUPPLEMENTARY SHEET	Amendment No. 24		
Authorized User(M.D.,D.O.,etc.)	Material and Use	~	
Mark G. Issa, D.O.	10 CFR 35.200		
Adil M. Karamali, M.D.	10 CFR 35.200 R REGU		
Allan Kaufman, M.D.	10 CFR 35.100,10 CFR 35.200	9>	
Blaine Keigley, M.D.	10 CFR 35.100,10 CFR 35.200	0	
Vincent Keiser, M.D.	CFR 35.100,10 CFR 35.200	The second se	
Steven Kumar-Jindal, M.D.	0 10 CFR 35.100,10 CFR 35.200	han	
John R. Letcher, M.D.	4 10 CFR 35.200		
Peter J. Longabaugh, M.D.	10 CFR 35 200	0	
Mohammed Maaieh, M.D.	10 CFR 35 200	NOIS	
Tamara Martin, M.D.	10 CFR 35.100,10 CFR 35,200		
Tarek S. Moustafa, M.D.	10 CFR 35.100,10 CFR 35.200	5	
Jonathon Naudad, M.D.	O 10 CFR 35.100,10 CFR 35.200	S S	
Thomas Pappas, M.D.	10 CFR 35.200	6	
Parag Parikh, M.D.	10 CFR 35.100,10 GFR 35.200	.0	
Yogesh P. Patel, M.D.	10 CFB 35.100,10 CFR 35.200	to a second s	
Timothy Quinn, M.D.	10 CFR 35,100,10 CFR 35,200		
Rubina Hassan Shah, M.D.	10 CFR 35.100,10 C₽R 35.200		
Steven K. Shekut, M.D.	10 CFR 35.100,10 CFR 35.200		<u>.</u>
Robin Shermis, M.D.	10 CFR 35.100,10 CFR 35.200		
Bruce R. Siders, D.O.	10 CFR 35.100,10 CFR 35.200		
Stephen Stoll, M.D.	10 CFR 35.100,10 CFR 35.200		
Michael A. Walsh, M.D.	10 CFR 35.100,10 CFR 35.200		
Thomas T. Win, M.D.	10 CFR 35.100,10 CFR 35.200		
Jonathon Yobbagy, M.D.	10 CFR 35.100,10 CFR 35.200		

NRC FORM 374A	U.S. NUCLEAR REGULAT	ORY COMMISSION	PAGE 4 OF 4 PAGES			
MATERIALS LICENSE	License Number 21-16642-01	Docket or Reference Number 030-11390				
SUPPLEMENTARY SHEET	Amendment No. 24					
<ul> <li>13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided form 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.</li> <li>A. Application dated February 2, 2011 (ML110470570)</li> <li>B. Letter dated April 30, 2012 (ML1213TA658)</li> <li>C. Letter dated January 11, 2017 (ML17017A140)</li> <li>E. Letter dated March 9, 2018 (ML1807TA131)</li> <li>F. Application dated February 22, 2019 (ML19056A539)</li> <li>Application dated February 22, 2019 (ML19056A539)</li> </ul>						
Date: <u>APR <b>0 9 2019</b></u>		FOR THE U.S. NUCLEAR REGULA By: Cassandra F. Frazier Region 3	TORY COMMISSION			